The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1664
ISSUE 1664
November 28, 2022
Issue 1664
- Antiviral Drugs for Influenza for 2022-2023
- Relyvrio for ALS
- In Brief: Alternatives to Adderall
- Comparison Chart: Antiviral Drugs for Influenza for 2022-2023 (online only)
- COVID-19 Update: Resistance to Bebtelovimab (online only)
- Maribavir (Livtencity) for Cytomegalovirus Infection (online only)
- Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
- Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Antiviral Drugs for Influenza for 2022-2023
November 28, 2022 (Issue: 1664)
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at increased risk for influenza complications (see
Table 1). Antiviral drugs recommended for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.